Dynavax Technologies (DVAX) Gross Profit Margin starting from the third quarter 2025 to third quarter 2024, Profitability Trends and Ranking, Fundamental Ratios - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Gross Margin
• EBITDA Margin
• Operating Margin
• Net Margin
• Pre-Tax Margin
• Effective Tax Rate
• Free Cash Flow Margin
• Cash Flow Margin
Dynavax Technologies Corporation  (NASDAQ: DVAX)


Dynavax Technologies's Gross Profit Margin by quarter

Trends, Rankings, Statistics


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

DVAX Gross Profit Margin (Sep 30 2025)
Q3 		(Jun 30 2025)
Q2 		(Mar 31 2025)
Q1 		(Dec 31 2024)
Q4 		(Sep 30 2024)
Q3
Y / Y Revenue Change 17.67 %
Seq. Revenue Change -0.59 %
Revenue In Millions $94.88
Gross Profit Margin 84.82 %
Gross Profit Margin Total Ranking # 508
Gross Profit In Millions $80.47
Y / Y Gross Profit Change 19.14 %
Seq. Gross Profit Change -1.15 %


Commenting Third Quarter 2025 Gross Profit Margin
Dynavax Technologies Corporation experienced contraction in Gross Profit by -1.15 % to $95 millions and Revenue by -0.59 %, while Gross Profit Margin fell to 84.82 %, above company*s average Gross Profit Margin.


Observing third quarter 2025 results within Major Pharmaceutical Preparations industry 52 other companies have achieved higher Gross Profit Margin. While Gross Profit Margin overall ranking has deteriorated relative to the three months before, from 483 to 508.
Learn about Gross Margin
DVAX's Gross Profit Margin third quarter 2025 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 53
Healthcare Sector # 85
Overall # 505

Gross Profit Margin Statistics
High Average Low
92.5 % 70.74 % 29.45 %
(Jun 30 2020)   (Mar 31 2019)


DVAX Gross Income Trends • More of DVAX's Profitabilty Ratios • DVAX Stock Quotes and Charts


Other Gross Profit Margin Profitability Ratios
DVAX's Cumulative Gross Profit Margin
Major Pharmaceutical Preparations Industry Gross Profit Margin Trends and Statistics
Healthcare Sector Gross Profit Margin Statistics
Gross Profit Margin Profitability Trends for overall market
DVAX's Gross Profit Margin Profitability versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Gross Profit Margin
Lowest Ranking Gross Profit Margin
Gross Profit Margin Profit Margin for DVAX's Competitors
Gross Profit Margin Profit Margin for Dynavax Technologies's Suppliers
Gross Profit Margin Profit Margin for DVAX's Customers

You may also want to know
DVAX's Annual Growth Rates DVAX's Profitability Ratios DVAX's Asset Turnover Ratio DVAX's Dividend Growth
DVAX's Roe DVAX's Valuation Ratios DVAX's Financial Strength Ratios DVAX's Gross Profit Growth
DVAX's Roa DVAX's Inventory Turnover Ratio DVAX's Growth Rates DVAX's Dividend Comparisons


Companies with similar Gross Profit Margin in the quarter ending Sep 30 2025, within Major Pharmaceutical Preparations Industry Gross Profit MarginSep 30 2025 MRQ Gross ProfitSep 30 2025 MRQ Revenue
Lexaria Bioscience Corp   100.00 %$ 0.174  Millions$ 0.174  Millions
Lexicon Pharmaceuticals Inc   99.93 %$ 14.172  Millions$ 14.182  Millions
Zai Lab Limited  99.90 %$ 115.976  Millions$ 116.095  Millions
Ptc Therapeutics inc   99.76 %$ 210.507  Millions$ 211.007  Millions
Kaya Holdings Inc   99.30 %$ 0.005  Millions$ 0.005  Millions
Travere Therapeutics Inc   99.04 %$ 163.274  Millions$ 164.859  Millions
Adc Therapeutics Sa  98.56 %$ 16.190  Millions$ 16.427  Millions
Ionis Pharmaceuticals Inc   98.51 %$ 154.381  Millions$ 156.719  Millions
Royalty Pharma Plc  98.01 %$ 597.156  Millions$ 609.291  Millions
Corcept Therapeutics Inc  97.79 %$ 203.042  Millions$ 207.638  Millions
Verastem Inc   97.42 %$ 10.952  Millions$ 11.242  Millions
Scienture Holdings Inc   97.39 %$ 0.575  Millions$ 0.590  Millions
One World Products Inc   97.25 %$ 0.049  Millions$ 0.050  Millions
Verrica Pharmaceuticals Inc   97.21 %$ 13.944  Millions$ 14.344  Millions
Ardelyx inc   96.39 %$ 106.347  Millions$ 110.329  Millions
Rafael Holdings Inc  96.25 %$ 0.231  Millions$ 0.240  Millions
Liquidia Corporation  95.78 %$ 52.047  Millions$ 54.342  Millions
Zevra Therapeutics Inc   95.25 %$ 24.825  Millions$ 26.063  Millions
Karyopharm Therapeutics Inc   95.20 %$ 41.931  Millions$ 44.044  Millions
Vanda Pharmaceuticals Inc   94.75 %$ 53.304  Millions$ 56.258  Millions
Avadel Pharmaceuticals Plc  94.69 %$ 73.351  Millions$ 77.467  Millions
Gyre Therapeutics Inc   94.67 %$ 28.936  Millions$ 30.564  Millions
Kyntra Bio Inc   94.61 %$ 1.018  Millions$ 1.076  Millions
Bridgebio Pharma Inc   94.56 %$ 114.137  Millions$ 120.700  Millions
Rigel Pharmaceuticals Inc  93.16 %$ 64.709  Millions$ 69.462  Millions
Axsome Therapeutics Inc   93.03 %$ 159.080  Millions$ 170.992  Millions
Ligand Pharmaceuticals Incorporated  92.99 %$ 107.364  Millions$ 115.461  Millions
Regeneron Pharmaceuticals Inc   92.52 %$ 3,473.300  Millions$ 3,754.300  Millions
Acadia Pharmaceuticals Inc   92.23 %$ 256.986  Millions$ 278.633  Millions
Arcutis Biotherapeutics Inc   91.25 %$ 90.534  Millions$ 99.219  Millions




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.